AI-Driven bioX Genetics Platform Slashes Genetic Variant Detection Time

bioXcelerate has unveiled the bioX Genetics Platform, which cuts the time needed to detect genetic variants by 98% and achieves 99% accuracy, leveraging AI-driven tools to accelerate drug discovery. Its advanced analytics streamline colocalisation analysis and fine-mapping from days to minutes, enhancing research efficiency. Researchers can securely analyze large datasets, advancing precision medicine for Alzheimer’s and Parkinson’s disease.

Traditionally, pinpointing disease-associated risk genes can be a laborious process, often requiring days of data wrangling and analysis. But with bioXcelerate’s new system, what once took days can now be done in minutes—backed by a remarkable 99% accuracy rate. This dramatic reduction in detection time not only accelerates the pace of research but also helps bring effective treatments to some of the most challenging neurological diseases.

Dr. Chris Foley, CEO at bioXcelerate, underscored the urgency of efficient data analysis in drug development: “Following the successful launch of Pleiograph we’re determined to continue our mission, giving patients the most effective treatments as soon as possible. Untapping maximum latent value from data relies on everyone working from the same page, using the right best-in-class tools to extract relevant insights efficiently.

Our new Genetics Platform recognises this and is designed to integrate seamlessly across R&D teams. Reducing the need to outsource disparate tools, it saves time and money while providing one accessible location to manage all datasets safely.”  

A Seamless, Secure Platform

At the heart of this breakthrough is the bioX Genetics Platform’s integrated research environment. Researchers can securely store, access, and analyze vast genetic datasets, spanning genome-wide association studies (GWAS) as well as eQTL and pQTL data. Advanced AI tools—such as SwitchStep and Pleiograph—are embedded directly within the platform, eliminating the need for fragmented workflows or third-party solutions.

From Days to Minutes

The platform’s advanced colocalisation analysis capability—key to understanding the spatial relationships of genetic variants and disease development—now takes minutes rather than days. Similarly, fine-mapping processes that once took up to two weeks can now be executed in under five hours.

Driving Precision Medicine Forward

By integrating robust AI analytics with scalable, compliant infrastructure, the bioX Genetics Platform exemplifies how digital innovation can reshape biomedical research. Researchers can now rapidly explore millions of genetic and molecular datasets, uncovering previously hidden correlations with unprecedented precision. This not only speeds up the identification of risk variants but also empowers teams to design more targeted therapies for patients in need.

The bioX Genetics Platform was unveiled today at investor BGF’s London office, drawing interest from leaders across pharma, healthcare, and biotech. Its promise is clear: to bridge the gap between genetic analysis and clinical impact, accelerating the arrival of life-changing treatments. For healthcare professionals and researchers, the bioX Genetics Platform offers a powerful new tool to tackle the complexities of genetic diseases.